Asked by: Lord Mott (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they plan to extend the current review period for prostate cancer screening to allow consideration of updated modelling that reflects contemporary NHS clinical practices.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The UK National Screening Committee’s consultation on their draft recommendation regarding prostate cancer screening was based on a model commissioned from Sheffield Centre for Health and Related Research. The model used contemporary National Health Service clinical practices including mpMRI following a prostate specific antigen test. There is therefore no need to extend the review period.
Asked by: Lord Taylor of Warwick (Non-affiliated - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the use of AI and assistive technologies in adult social care and elderly support services, in particular its impact on improving independence and quality of life for older people.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Artificial intelligence (AI) and assistive technologies can support people to live high-quality, independent lives for longer. Such technologies are already being used across adult social care by care providers and local authorities to enable more preventative and personalised care, save staff time, and improve care coordination.
To help assess the use of technologies in adult social care, the Government has funded testing and evaluation of technologies in social care, including AI-enabled technologies, through the Adult Social Care Technology Fund. Emerging evidence indicates positive outcomes for people in receipt of care, care professionals, and the wider health and social care system. People using technology experienced greater independence, safety, wellbeing, and quality of life. We will publish the findings from these projects.
The Government is committed to supporting safe and appropriate adoption of technologies in social care. We are setting new national standards for care technologies and producing trusted guidance, so that people can confidently buy and use technology which support them or the people they care for. To support appropriate use of AI in adult social care, we have published guidance for care providers on AI use cases and tips for safe and responsible use. We will be setting out the Government’s strategic approach to AI in adult social care, alongside its approach to AI in health, through the National AI Roadmap. We have also launched the Adult Social Care Assessments Improvement Toolkit to help local authorities find digital and AI-enabled tools to improve services and the quality-of-care delivery.
Asked by: Lord Mott (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they plan to invite independent economic and clinical reviewers to assess revisions to the prostate cancer screening model before a final recommendation is made by the UK National Screening Committee.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government has made it clear that it would like to see screening in place for prostate cancer where it is supported by the evidence.
The UK National Screening Committee (UK NSC) consulted on their draft recommendation regarding prostate cancer screening which was based on a model commissioned from Sheffield Centre for Health and Related Research (SCHARR). SCHARR included expert economists and clinicians in workshops throughout the model’s development. The UK NSC ran a series of workshops with economists, academics, and clinicians to examine the model’s structure, evidence, assumptions, and conclusions. It also ran a 12-week public consultation on their draft recommendation and evidence package. Upon request, York Health Economics Consortium were given access to the underpinning model and York, as well as Prostate Cancer Research who funded York’s work, have submitted findings to the consultation. Updates have been made on the basis of comments which have been shared with experts. These findings will be considered alongside the other submissions to the consultation before UK NSC make a final recommendation based on the current evidence base.
The model will be maintained and interrogated as new evidence becomes available. The UK NSC is committed to keeping prostate cancer screening under review.
Asked by: Juliet Campbell (Labour - Broxtowe)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support the availability of Peer Supported Open Dialogue in the NHS.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
There is no national policy specifically focused on implementing Peer Supported Open Dialogue.
The National Health Service follows evidence when implementing any approach at scale and will respond to any future changes in National Institute for Health and Care Excellence guidance. A research trial evaluating the impact of open dialogue in the NHS is due to report soon, at the following link:
Nationally, we are committed to working with local NHS mental health providers to develop a new approach for mental health in 2026, including through the upcoming modern service framework for severe mental illness.
The Department is also supporting the development of the evidence base on mental health care through research and evaluation, including studies funded by the National Institute for Health and Care Research, to inform future decisions on effective models of care.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when digital prescriptions will be available in all NHS hospitals.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England does not have a target date for digital prescription availability in all National Health Service hospitals. The NHS Digital Maturity Assessment 2025 showed that 93% of NHS hospital trusts have gone live with an electronic prescribing and medicines administration system. The 2026 Digital Maturity Assessment will provide the latest data later this year.
Asked by: Will Forster (Liberal Democrat - Woking)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of commissioning controls, including Indicative Activity Plans, on access to children’s ADHD and autism assessments.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Patients have a legal Right to Choose their provider when referred for National Health Service funded eligible care.
In 2023, NHS England published National framework and operational guidance for autism assessment services aimed at supporting those in commissioning roles during their commissioning cycles and operational guidance to support and inform decision-making at service level. These two guidance documents are available, respectively, at the following two links:
https://www.england.nhs.uk/publication/autism-diagnosis-and-operational-guidance/
Integrated care boards are responsible for ensuring that their processes comply with the legal Right to Choose.
NHS England is aware that commissioning controls on levels of assessment activity have been set by some commissioners and is working with systems to develop a supporting document to the NHS Payment Scheme 2026/27 statutory consultation to help identify the costs associated with undertaking autism and attention deficit hyperactivity disorder (ADHD) assessments. This aims to help guide the pricing and create a more equitable and consistent approach to the autism and ADHD assessment payment process. NHS England published the NHS Standard Contract which requires integrated care boards (ICBs) to agree indicative activity plans (IAPs) for any service area which is variably funded, to aid in planning and capacity and demand management. IAPs are planning tools which do not restrict activity carried out by a provider.
The NHS Medium Term Planning Framework requires ICBs to undertake thorough demand and capacity planning and to strategically commission services that meet the needs of their patient population. ICBs may need to prioritise certain areas of care for their patient population, which may include managing planned assessment activity in some areas through Activity Management Plans.
My Rt Hon. Friend, the Secretary of State for Health and Social Care, announced on 4 December 2025 the launch of an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism. This independent review will inform our new approach to mental health, so people receive the right support, at the right time and in the right place. Likewise, the review will inform our approach so that people with ADHD and autistic people have the right support in place to enable them to live well in their communities.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of Shared Care Agreements for patients prescribed ADHD medication by an independent sector provider under a) NHS Right to Choose and b) privately funded arrangements.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Shared care within the National Health Service refers to a voluntary arrangement whereby a specialist may transfer responsibility for aspects of a patient’s care, such as prescription of medication, to the patient’s general practitioner (GP). Decisions regarding shared care agreements are made locally, and the General Medical Council has made it clear that GPs are not contractually obliged to enter shared care agreements and may decline requests on clinical or capacity grounds.
No specific assessment has been made of the effectiveness of shared care agreements with independent sector providers for patients prescribed attention deficit hyperactivity disorder (ADHD) medication.
NHS England established an ADHD taskforce bringing together people with lived experience with experts from across sectors to better understand the challenges in accessing timely and equitable support.
In addition, on 4 December 2025 my Rt Hon. Friend, the Secretary of State for Health and Social Care, announced an independent review into the prevalence and support for mental health conditions, ADHD, and autism, which will inform our approach to ensuring appropriate support is in place.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the pausing of Shared Care Agreements for ADHD on patients.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Shared care within the National Health Service refers to a voluntary arrangement whereby a specialist may transfer responsibility for aspects of a patient’s care, such as prescription of medication, to the patient’s general practitioner (GP). Decisions regarding shared care agreements are made locally, and the General Medical Council has made it clear that GPs are not contractually obliged to enter shared care agreements and may decline requests on clinical or capacity grounds.
No specific assessment has been made of the effectiveness of shared care agreements with independent sector providers for patients prescribed attention deficit hyperactivity disorder (ADHD) medication.
NHS England established an ADHD taskforce bringing together people with lived experience with experts from across sectors to better understand the challenges in accessing timely and equitable support.
In addition, on 4 December 2025 my Rt Hon. Friend, the Secretary of State for Health and Social Care, announced an independent review into the prevalence and support for mental health conditions, ADHD, and autism, which will inform our approach to ensuring appropriate support is in place.
Asked by: Freddie van Mierlo (Liberal Democrat - Henley and Thame)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Early Access to Medicines Scheme in facilitating patient access to new treatments for neuromuscular diseases.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Medicines and Healthcare products Regulatory Agency (MHRA) supports access to treatments for people living with neuromuscular diseases. The majority of neuromuscular diseases are defined as rare diseases. On the 2 November 2025, the MHRA published a policy paper on rare therapies and United Kingdom regulatory considerations, which is available at the following link:
The Early Access to Medicines Scheme (EAMS), is an existing pathway across the regulatory and access system designed to support innovative treatments being available to patients earlier in the development cycle, outside of a clinical trial. This includes for those living with neuromuscular diseases. The Government is collaborating across the regulatory system to continuously review the effectiveness of these pathways for rare diseases. Further information on the EAMS is available at the following link:
https://www.gov.uk/guidance/apply-for-the-early-access-to-medicines-scheme-eams
Asked by: Danny Chambers (Liberal Democrat - Winchester)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to take steps to ensure that AI-based mental health tools do not replace access to human-delivered psychological support where this is clinically appropriate.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is clear that artificial intelligence (AI) based tools must not replace access to human‑delivered psychological support where this is clinically appropriate.
Digital and AI tools can be used to support mental health services and those in need of those services, for example by helping with administrative tasks, triage, or appointment management, and these benefits can enable clinicians to spend more time delivering direct care. However, decisions about treatment and care must always be clinically led and based on individual patient need.
Publicly available AI applications that are not deployed by the National Health Service, such as ChatGPT or Google Gemini, are not regulated as medical technologies and may offer incorrect or harmful information. People experiencing mental health difficulties are strongly encouraged to seek support from qualified professionals through NHS services or trusted charities.
Spending across mental health services, both specialised commissioning and ICB combined, and including learning disability, autism, and dementia, is planned to increase to £20.616 billion in 2025/26, compared to £18.988 billion in 2024/25. Specific funding has also been allocated to expand mental health support in schools to 100% of institutions by 2029/30.